ACAT1 and neoplasm: Combination treatment of ACAT1 inhibitor and sorafenib could significantly inhibit tumor growth in HCC xenografts, indicating that pharmaceutical inhibition of ACAT1 could be a promising target in anti-HCC strategy (17).